From the above transcript, Here are the parts that mentioned...

From the above transcript, Here are the parts that mentioned ATL1103

B Lynne Parshall
"In 2012, we’ll have two differen drugs go into later stage clinical trials both our TTR program, as well as our partners at ATL, their acromegaly drug. We’ll have two drugs from which we plan to have data this year, "

Stanley T Crooke
"Our partners at ATL have reported there is a growth hormone receptor drug lowered circulating levels of growth hormone receptor and all of the downstream consequences that you would expect from that. Those of you who know anything about the treatment of acromegaly know that a better, better tolerated safer treatment for acromegaly is desperately needed, our partners at ATL are progressing in Phase II program on this disease."

And the Antisense technology we have been discussing and its implication for ANP with 3 antisense compounds:

"So now I want to finish with the technology. Of course, everything we do has a technology component to it, and we continue everyday to invest in our technology. We’ve invented this and we continue to enhance it. We don’t know that second generation antisense drugs worked. This table shows 13 different targets to 13 different drugs to 13 different targets in which we have evidence, clinical evidence of antisense activity that is lowering the target.

So that’s multiple drugs, multiple targets, multiple tissues, multiple clinical trials, multiple analytes, and multiple partners. In fact, with Mipomersen as you’ve heard, we’ve actually completed 20 positive clinical trials. So we know that second generation antisense drugs are working, they are working broadly, and they’re working at doses that have this attractive safety and tolerance profiles."